ZZ
Therapeutic Areas
TScan Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TSC-101 | Hematologic malignancies (Acute Myeloid Leukemia, Myelodysplastic Syndromes) | Phase 1 |
| TSC-102-A01 | Hematologic malignancies | Preclinical |
| TSC-102-A03 | Hematologic malignancies | Preclinical |
| Multiple Unnamed TCR-T Candidates | Solid Tumors | Preclinical |
| In Vivo-Engineered T Cell Programs | Not Specified (Likely Cancer) | Preclinical |
| Autoimmune Disease Programs | Autoimmune Disorders | Discovery |
Leadership Team at TScan Therapeutics
GM
Gavin MacBeath
Chief Executive Officer
JA
Jason Amello
Chief Financial Officer and Treasurer
CL
Chrystal Louis
Chief Medical Officer
SC
Stephen Camiolo
Senior Vice President, Market Access
SC
Shrikanta Chattopadhyay
Senior Vice President, Head of Translational Medicine
CG
Cagan Gurer
Senior Vice President, Discovery
AH
Ann Hargraves
Senior Vice President, Human Resources
RL
Ray Lockard
Senior Vice President, Head of Quality
JM
Jim Murray
Senior Vice President, Head of Development Operations
SB
Stephen Biggar
Partner at Baker Bros. Advisors LP (Board of Directors)